Package Leaflet: Information for theuser
PENTASA1 gramsuspensionrectal
Mesalazine
Read all of this leaflet carefully before you start usingthis medicine because it contains important information for you.
Contents of the pack
PENTASA rectal suspension is indicated for the treatment of ulcerative colitis localized in the rectum and sigmoid colon.
Ulcerative colitis is an inflammatory bowel disease in which the lining of the intestine is inflamed and develops many small breaks in its surface (ulcers) that can bleed.
Pentasa contains the active ingredient mesalazine, which belongs to the group of medicines called intestinal anti-inflammatory agents that help reduce inflammation and painful symptoms.
Do not use PENTASA rectal suspension:
Warnings and precautions
Consult your doctor or pharmacist before starting to use Pentasa rectal suspension:
Mesalazine may cause a discoloration of the urine to a reddish-brown color after contact with sodium hypochlorite bleach in the toilet water. This is a chemical reaction between mesalazine and bleach and is harmless.
Be careful with mesalazine:
Severe skin reactions, such as drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SSJ), and toxic epidermal necrolysis (NET), have been observed with mesalazine treatment. Stop taking mesalazine and seek medical attention immediately if you observe any of the symptoms related to these severe skin reactions described in section 4.
If you experience severe or recurrent headache, vision changes, or ringing or buzzing in the ears, contact your doctor immediately.
While you are being treated with this medicine, your doctor will perform blood and urine tests to monitor your kidney function, especially at the start of treatment.
Use in children:
There is limited documentation on the effect in children (6-18 years).
Use in elderly:
It should be used with caution in the elderly and only in patients with normal kidney function.
Use of Pentasa with other medicines:
Tell your doctor or pharmacist if you are using or have recently used or may need to use any other medicine.
This is especially important if you are taking any of the following medicines:
This is not applicable.
Pregnancy, breast-feeding, and fertility
If you are pregnant or breast-feeding, or think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.
There is limited experience with the use of mesalazine during pregnancy and breast-feeding.
Blood disorders have been observed in newborns of mothers treated with this medicine.
Newborns may develop allergic reactions after breast-feeding, for example diarrhea. If the newborn presents with diarrhea, breast-feeding should be discontinued.
Fertility:
Mesalazine data in animals show that it has no effect on male or female fertility.
Driving and using machines:
Treatment with Pentasa rectal suspension does not appear to have any influence on the ability to drive or use machines.
Follow the instructions for administration of this medicine exactly as indicated by your doctor. If you are in doubt, consult your doctor or pharmacist again. Remember to use your medicine.
The rectal suspension sachets are protected by an aluminum bag and should be used immediately after opening.
It is recommended to evacuate before administering the rectal suspension.
Instructions for use
|
|
|
|
|
|
|
|
Note: It is recommended to protect bedding from possible spills, as Pentasa rectal suspension may discolor fabrics. If Pentasa rectal suspension is accidentally spilled on fabric, soak it immediately.
The recommended dose is:
Adults: 1 sachet of rectal suspension of 100 milliliters (1 gram) at bedtime for 2-3 weeks. The dose may be reduced depending on the patient's body weight.
Children (6-18 years): There is limited experience and documentation on the effect in children.
The dosage should be adjusted according to the patient's response.
No cases of overdose have been reported in humans, but if an overdose is suspected, consult a doctor.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medicine and the amount ingested.
If you stop treatment with Pentasa rectal suspension
Your doctor will indicate the duration of your treatment with Pentasa rectal suspension. Do not stop treatment before, even if you feel better, as symptoms may return if treatment is stopped too soon. Follow your doctor's instructions strictly for the maintenance time established.
If you have any further questions about the use of this product, ask your doctor or pharmacist.
Like all medicines, Pentasa rectal suspension can cause side effects, although not everybody gets them.
Serious side effects:
Very few cases of severe allergic reaction (including severe skin erosion that can affect the skin as a protective barrier of the body) have been reported. The allergic reaction could lead to swelling of the face and neck and/or difficulty breathing or swallowing (angioedema). If this happens, contact your doctor or emergency service immediately.
Tell your doctor immediately if you experience severe or recurrent headache, vision changes, or ringing or buzzing in the ears. These could be symptoms of increased pressure inside your skull (idiopathic intracranial hypertension).
Stop taking mesalazine and seek medical attention immediately if you present any of the following symptoms:
The following frequent side effectsaffect between 1 and 10 in every 100 patients treated:
The following rare side effectsaffect between 1 and 10 in every 10,000 patients treated:
The following very rare side effectsaffect less than 1 in 10,000 patients treated:
Frequency not known(cannot be estimated from the available data)
Some of these adverse reactions may also be attributed to the disease itself.
If these symptoms continue or become more severe, consult your doctor.
Reporting of side effects:
If you experience any side effects, talk to your doctor or pharmacist, even if it is possible side effects not listed in this leaflet. You can also report side effects directly through the Spanish Pharmacovigilance System for Human Use Medicines: http;//www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep out of the sight and reach of children.
Do not store above 25°C. Do not refrigerate or freeze. Keep in the original container to protect from light.
Do not use this medicine after the expiry date which is stated on the container after “EXP”. The expiry date is the last day of the month shown.
Medicines should not be disposed of via wastewater or household waste. Return any unused containers and medicines to your pharmacist. Ask your pharmacist how to dispose of medicines no longer required. This will help to protect the environment.
Composition of PENTASA rectal suspension:
-The other ingredients are: disodium edetate, sodium metabisulfite (E-223), sodium acetate, hydrochloric acid, and purified water c.s.p. 100 milliliters.
Appearance and packaging of the product
PENTASA rectal suspension is a white to slightly yellowish suspension of 100 milliliters for rectal administration.
Each box contains 7 sachets of rectal suspension of 100 milliliters.
Marketing authorization holder
Ferring S.A.U
C/ del Arquitecto Sánchez Arcas nº3, 1º
28040 Madrid
Spain
Manufacturer:
Ferring Léciva a.s
Address: K Rybníku 475, 252 42
Jesenice near Prague, Czech Republic
Date of last revision of this leaflet: January 2025
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/